alemtuzumab Injection [Lemtrada]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system which leads to demyelination and neurodegeneration…
Tras finalizar la evaluacion europea del balance beneficio-riesgo de alemtuzumab (Lemtrada®) se recomienda
restringir la…
La gravedad de los casos identificados ha motivado el inicio de una revisión detallada de la información disponible a nivel…
U pstream targeting of both T and B cells is a rational therapeutic approach in multiple sclerosis (MS) in view of how both cell…
BackgroundAlemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In…
Twenty-four approved monoclonal antibodies (mAbs) not indicated for cancer therapy are specific for a total of 20 different…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, today announced posit ive new five-year investigational data from…